Pharmafile Logo

KOL Strategy

- PMLiVE

LifeArc to launch rare disease centres across the UK

One in 17 people will be affected by a rare disease at some point in their lives, amounting to around 3.5 million people in the UK

- PMLiVE

Sharing Outcomes in MS at ECTRIMS 2023

During ECTRIMS 2023 congress, the Medscape Education Global team will be on site to present a poster of their educational outcomes.The poster, Virtual Patient Simulation Improves Neurologists’ Performance in Making...

Medscape Education

- PMLiVE

Shining a Light on Current Topics in Oncology

The Medscape Oncology team will be on the road again, this time in Madrid, Spain for ESMO 2023. This year, the team will be sharing education with a deep impact...

Medscape Education

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

- PMLiVE

Roche presents positive results for spinal muscular atrophy treatment Evrysdi in babies

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Nanobiotix shares promising results for radiotherapy enhancer in advanced pancreatic cancer

More than 90% of patients with locally advanced disease are not eligible for surgery

- PMLiVE

BioIndustry Association reveals how UK is set to become a global leader in mRNA

Several companies and organisations have supported the development of mRNA

The AI Roadmap – charting our future in healthcare communications

The HCA has published a new position paper on the use of AI within the sector

- PMLiVE

Executive Insight Healthcare Consultants promotes Philippe Coune to partner

Coune first joined the company in 2013 as a consultant

- PMLiVE

Harnessing the power of AI in clinical trials

Fareed Melhem talks about how artificial intelligence can help to reduce the burden of trials on patients

- PMLiVE

Learning from the best: seven steps to exceptional launches

Repurposing ‘YOLO’ to stand for ‘You Only Launch Once’

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links